<?xml version="1.0" encoding="UTF-8"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9"
        xmlns:news="http://www.google.com/schemas/sitemap-news/0.9"
        xmlns:image="http://www.google.com/schemas/sitemap-image/1.1">
  <url>
    <loc>https://www.pharmanow.live/latest-news/ektah-advances-nks3-obesity-drug-phase-iia-24-million-funding</loc>
    <lastmod>2026-11-18T22:38:18+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>EktaH Advances NKS-3 Obesity Drug into Phase IIa After Securing €2.4 Million Funding</news:title>
      <news:keywords>EktaH</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/4a4e6ff9-3c0b-4aff-8ad3-6dba185a7d76/aa25711f-9e4a-46fd-bda4-2be5f46da69a.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/innate-pharma-iph4502-phase-1-data-ena-2026-adc-linker-stability</loc>
    <lastmod>2026-11-18T22:37:40+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Innate Pharma Achieves Phase 1 Milestone for IPH4502 ADC with Linker Stability Signal</news:title>
      
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/b81fc5d2-298e-4f8b-aa9e-df24b0516083/310d4df5-7ea9-48e6-bac1-9abfa2dce967.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/merck-discontinues-bellwave-011-phase-3-nemtabrutinib-dmc-review</loc>
    <lastmod>2026-11-18T22:39:08+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Merck Discontinues BELLWAVE-011 Phase 3 Trial for Nemtabrutinib</news:title>
      <news:keywords>Merck</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/3896d5ab-53f2-4967-9e8a-feaebf0f363c/6b8af12f-ccf8-4f62-b9de-2944ddbc7d53.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-launches-global-reliance-disclosure-program-nme-bla-january-2027</loc>
    <lastmod>2026-11-18T22:40:41+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>FDA Launches Global Reliance Disclosure Program, Expanding NME and BLA</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/ddff00b4-40c4-4240-8eb5-9508141d5762/26a146c8-ae41-4860-8d15-5ca931d303eb.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/fda-draft-guidance-bayesian-methodology-clinical-trials-drug-biologics</loc>
    <lastmod>2026-11-18T22:41:29+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>FDA Issues Draft Guidance on Bayesian Methodology for Drug and Biologics Clinical Trials</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/f5104fc5-ab3a-4193-be94-8ba4763d084c/c8e2257a-182e-4889-a0ab-18ad60f745a8.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/nuvalent-fda-accelerated-approval-neladalkib-alk-positive-nsclc</loc>
    <lastmod>2026-11-18T22:47:57+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Nuvalent Gains FDA Accelerated Approval for Neladalkib in NSCLC</news:title>
      <news:keywords>Nuvalent</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/f5104fc5-ab3a-4193-be94-8ba4763d084c/d194beca-5702-4c5e-985a-a07e38ebf0e3.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/mandos-fda-approval-lembaz-infantile-onset-niemann-pick-disease-type-c</loc>
    <lastmod>2026-11-18T22:48:57+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Mandos Gains FDA Approval for Lembaz in Infantile-Onset Niemann-Pick Disease Type C</news:title>
      <news:keywords>Mandos</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/f5104fc5-ab3a-4193-be94-8ba4763d084c/b0959468-8bc1-498d-9f2c-17effc35e5ee.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/viatris-acquires-pacira-biosciences-exparel-iovera-deal-complete</loc>
    <lastmod>2026-11-18T22:50:30+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-18T00:00:00+05:30</news:publication_date>
      <news:title>Viatris Acquires Pacira BioSciences, Adding EXPAREL and iovera° to Portfolio</news:title>
      <news:keywords>Viatris</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://newsroom.viatris.com/file.php/181193/Refreshed_Viatris_Logo_thumb.png?thumbnail=144</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/greenwich-lifesciences-sabcs-2026-flamingo-01-abstracts</loc>
    <lastmod>2026-11-18T22:55:03+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Greenwich LifeSciences Secures Abstract Acceptances for Phase III FLAMINGO-01 Trial</news:title>
      <news:keywords>Greenwich</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/24d50f14-aa70-4149-88ca-9b696c150099/4b6cde01-0417-4272-bb33-9735e2e8d6f1.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/hikma-umang-vohra-board</loc>
    <lastmod>2026-11-17T15:24:34+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Hikma Pharmaceuticals Appoints Ex-Cipla CEO Umang Vohra to Board</news:title>
      <news:keywords>Hikma Pharmaceuticals, Umang Vohra, Cipla, Non-Executive Director, Board of Directors, Cohance Lifesciences, generic pharmaceuticals</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/hikma-umang-vohra-board-appointment20261117152302.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/bioxcel-therapeutics-fda-approval-at-home-agitation-treatment-schizophrenia-bipolar</loc>
    <lastmod>2026-11-18T22:37:07+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Bioxcel Therapeutics Gains FDA Approval for First At-Home Agitation Treatment in Schizophrenia and Bipolar Disorder</news:title>
      <news:keywords>Bioxcel</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/b9430af6-4c73-476f-b08b-3759fc03799e/a26db997-8859-4031-bffe-9c8b3068f197.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ideaya-biosciences-fda-type-c-ide849-registrational-strategy-neuroendocrine-carcinomas</loc>
    <lastmod>2026-11-18T12:08:42+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>IDEAYA Biosciences Aligns with FDA on IDE849 Trial Strategy</news:title>
      <news:keywords>IDEAYA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ideaya-ide849-fda-type-c-nec-registrational-trial-strategy20261118120309.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/genentech-fda-approval-giredestrant-everolimus-esr1-mutated-metastatic-breast-cancer</loc>
    <lastmod>2026-11-18T11:55:21+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>FDA Approves Giredestrant Plus Everolimus for Breast Cancer</news:title>
      <news:keywords>FDA</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-giredestrant-wilserdly-everolimus-esr1-breast-cancer-approval20261118115412.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/cue-biopharma-phase-2-csu-durability-data-cue-401-first-in-human-dosing</loc>
    <lastmod>2026-11-18T11:45:59+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Cue Biopharma Reports Phase 2 CSU Data and CUE-401 Dosing</news:title>
      <news:keywords>Cue Biopharma</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/cue-biopharma-cue-221-csu-durability-cue-401-phase-1-dosing20261118114346.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/mankind-pharma-signs-exclusive-india-deal-betta-pharmaceuticals-ensartinib-alk-nsclc</loc>
    <lastmod>2026-11-18T11:40:20+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Mankind Pharma Secures Exclusive India Rights for Ensartinib</news:title>
      <news:keywords>Mankind</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/mankind-pharma-ensartinib-betta-india-licensing-deal-alk-lung-cancer20261118113652.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/lantheus-achieves-phase-3-endpoints-tauklarify-tau-pet-early-alzheimers</loc>
    <lastmod>2026-11-18T11:26:14+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>Lantheus Meets Phase 3 Endpoints for TAUKLARIFY PET</news:title>
      <news:keywords>Lantheus</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/lantheus-tauklarify-phase-3-early-alzheimers-tau-pet-results20261118112442.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/ucb-fda-approval-klygefa-dual-binding-nanobody-c5-inhibitor-gmg</loc>
    <lastmod>2026-11-17T11:29:01+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-17T00:00:00+05:30</news:publication_date>
      <news:title>UCB Gains FDA Approval for Klygefa as First Dual-Binding Nanobody C5 Inhibitor</news:title>
      <news:keywords>UCB</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/bf9c78ec-f5fb-44f9-8827-7c34bfabed8b/2981ecf6-4533-40b9-bcba-3c3ded747cc1.png</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/novartis-cosentyx-chmp-positive-opinion-adolescent-hidradenitis-suppurativa-europe</loc>
    <lastmod>2026-11-18T11:20:02+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T00:00:00+05:30</news:publication_date>
      <news:title>Novartis Gains Positive CHMP Opinion for Cosentyx in Adolescents</news:title>
      <news:keywords>Novartis</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/novartis-cosentyx-chmp-opinion-adolescent-hidradenitis-suppurativa20261118111904.webp</image:loc>
    </image:image>
  </url>
  <url>
    <loc>https://www.pharmanow.live/latest-news/evotec-secures-2-9-million-gates-foundation-grant-stem-cell-fetal-safety-screening</loc>
    <lastmod>2026-11-18T11:05:09+05:30</lastmod>
    <news:news>
      <news:publication>
        <news:name>Pharma Now</news:name>
        <news:language>en</news:language>
      </news:publication>
      <news:publication_date>2026-11-16T00:00:00+05:30</news:publication_date>
      <news:title>Evotec Secures $2.9M Grant for Stem Cell Fetal Safety</news:title>
      <news:keywords>Evotec</news:keywords>
    </news:news>
    
    <image:image>
      <image:loc>https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/evotec-gates-foundation-grant-stem-cell-fetal-safety-screening20261118110329.webp</image:loc>
    </image:image>
  </url>
</urlset>